Skip to main content
Fig. 2 | Biology Direct

Fig. 2

From: MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression

Fig. 2

Depletion of MAP7D3 impairs in vitro metastasis traits of the highly metastatic IV2 and 468-LN cells. (A) Western blotting analysis of MAP7D3 protein expression in the control IV2 cells and the stable MAP7D3 knockdown IV2 cells. (B) Cell proliferation of the control IV2 cells and the stable MAP7D3 knockdown IV2 cells. (C) Soft agar assay of the control IV2 cells and the stable MAP7D3 knockdown IV2 cells. Scale bar, 1000 μm. (D) Western blotting analysis of MAP7D3 protein expression in the control 468-LN cells and the stable MAP7D3 knockdown 468-LN cells (E) Cell proliferation analysis of the control 468-LN cells and the stable MAP7D3 knockdown 468-LN cells. (F) Soft agar assay of the control 468-LN cells and the stable MAP7D3 knockdown 468-LN cells. Scale bar, 1000 μm. (G) Tranwell migration assay of the control IV2 cells and the stable MAP7D3 knockdown IV2 cells. Scale bar, 200 μm. (H) Matrigel-coated Tranwell assay of the control IV2 cells and the stable MAP7D3 knockdown IV2 cells. Scale bar, 200 μm. (I) Tranwell migration assay of the control 468-LN cells and the stable MAP7D3 knockdown 468-LN cells. Scale bar, 200 μm. (J) Matrigel-coated Tranwell migration assay of the control 468-LN cells and the stable MAP7D3 knockdown 468-LN cells. Scale bar, 200 μm. * P < 0.05. Each experiment was performed in triplicate and repeated three times

Back to article page